Tesevatinib
- Generic Name
- Tesevatinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25Cl2FN4O2
- CAS Number
- 781613-23-8
- Unique Ingredient Identifier
- F6XM2TN5A1
- Background
Tesevatinib has been used in trials studying the treatment of Cancer, Stomach Cancer, Brain Metastases, Esophageal Cancer, and Leptomeningeal Metastases, among others.
...
- Associated Conditions
- -
- Associated Therapies
- -
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
- Conditions
- Interventions
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Kadmon, a Sanofi Company
- Target Recruit Count
- 80
- Registration Number
- NCT03203642
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸California Institute for Renal Research, La Mesa, California, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT03096080
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2016-07-26
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT02844439
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Center for Neurosciences, Tucson, Arizona, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
- Conditions
- Interventions
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT02616393
- Locations
- 🇺🇸
Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸USC Norris Oncology/Hematology Newport Beach, Newport Beach, California, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
- Conditions
- Interventions
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT02616055
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT02154529
- Locations
- 🇺🇸
Laura and Isaac Perlmutter Cancer Center @ NYU Langone, New York, New York, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸San Juan Oncology, Farmington, New Mexico, United States
A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Kadmon, a Sanofi Company
- Target Recruit Count
- 69
- Registration Number
- NCT01559363
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of Colorado Denver, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.